Aspect Partners’s ARS Pharmaceuticals SPRY Stock Holding History

Aspect Partners’s Portfolio SPRY Stock Details SPRY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-200	Closed	-$2.11K	–	654
2024 Q4	$2.11K	Buy	+200	New	+$2.8K	﹤0.01%	470

Other funds holding SPRY

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

SOCM

SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

Aspect Partners's SPRY Position: Q1 2025 in Review

Aspect Partners sold out of ARS Pharmaceuticals (SPRY) in Q1 2025, closing a stake of 200 shares — an estimated $2.11K sold.

Aspect Partners first reported a position in SPRY in Q4 2024 and held it in 1 quarter. The position peaked at $2.11K in Q4 2024. 184 funds tracked by Wall St. Rank hold SPRY as of Q1 2025.

Aspect Partners reported no remaining ARS Pharmaceuticals position as of Q1 2025 after selling out during the quarter.
Aspect Partners sold 200 ARS Pharmaceuticals shares in Q1 2025, an estimated $2.11K.
Aspect Partners first reported a position in ARS Pharmaceuticals in Q4 2024 and held it in 1 quarter.
Aspect Partners's ARS Pharmaceuticals position peaked at $2.11K in Q4 2024.
184 funds tracked by Wall St. Rank held ARS Pharmaceuticals as of Q1 2025.

Based on Aspect Partners's 13F filing for Q1 2025, filed 24 Apr 2025.